SCHEMBL5901151

SCHEMBL5901151

CCCCCCn1nnc(C(C(=O)Nc2cc(C)c(O)c(C)c2C)c2ccccc2)n1

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SOAT2 O75908 1/20 0.56
ACAT1 P24752 1/20 0.56
SOAT1 P35610 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5900890 1.00 SOAT2 (0.56) SOAT2ACAT1SOAT1
SCHEMBL5900949 1.00 SOAT2 (0.56) SOAT2ACAT1SOAT1
SCHEMBL6941039 0.83
SCHEMBL6942238 0.81
Hydrochloric Acid SCHEMBL5900881 0.80
SCHEMBL6939463 0.80
SCHEMBL7077869 0.80
SCHEMBL5972843 0.79
SCHEMBL6940716 0.79
SCHEMBL6246993 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135785-A1 Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof PIERRE FABRE MEDICAMENT (FR) 2006-06-22 US claimed
US-20060135785-A1 Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof PIERRE FABRE MEDICAMENT (FR) 2006-06-22 US disclosed
EP-1558590-A1 ALPHA-PHENYL ACETANILIDE DERIVATIVES HAVING AN ACAT INHIBITING ACTIVITY AND THE THERAPEUTIC APPLICATION THEREOF PIERRE FABRE MEDICAMENT (FR) 2005-08-03 EP disclosed
WO-2004035552-A1 ALPHA-PHENYL ACETANILIDE DERIVATIVES HAVING AN ACAT INHIBITING ACTIVITY AND THE THERAPEUTIC APPLICATION THEREOF PIERRE FABRE MEDICAMENT (FR) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135785-A1 Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof ACAT2, ACAT1, LCAT SOAT2 109/4885ACAT1 2/4885SOAT1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.